StoxFortis Healthcare vs Anthem Biosciences: share price & financials comparison
NSE: FORTIS vs ANTHEM · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Fortis Healthcare vs Anthem Biosciences at a glance
Fortis Healthcare (FORTIS) has a market capitalisation of ₹57,898 Cr, against ₹51,594 Cr for Anthem Biosciences (ANTHEM). Over the past year Anthem Biosciences has returned +26.0%, compared with -27.3% for Fortis Healthcare. On valuation, Fortis Healthcare trades at a lower P/E of 55.8 versus 271.9. Fortis Healthcare earns a higher return on equity (9.9% vs 5.8%). Fortis Healthcare comes out ahead on size, valuation, profitability and growth. Anthem Biosciences comes out ahead on financial health, momentum and technicals. Across the scored metrics below, Fortis Healthcare leads on 6 and Anthem Biosciences on 6. On StoxGud's 10-point checklist, Fortis Healthcare scores 4/10 and Anthem Biosciences scores 6/10.
| Metric | Fortis Healthcare | Anthem Biosciences |
|---|---|---|
| Size | ||
| Market cap | ₹57,898 Cr | ₹51,594 Cr |
| Revenue (latest FY) | ₹9,128 Cr | ₹2,124 Cr |
| Net profit (latest FY) | ₹1,042 Cr | ₹592 Cr |
| Valuation | ||
| P/E | 55.8 | 271.9 |
| P/B | 5.53 | 15.73 |
| Dividend yield | 0.13% | — |
| Profitability | ||
| Return on equity | 9.9% | 5.8% |
| Net profit margin | 10.5% | 9.3% |
| Operating margin | 22.2% | 41.4% |
| Growth | ||
| Revenue growth (YoY) | +17.3% | +8.0% |
| Net profit growth (YoY) | -3.0% | — |
| Revenue CAGR (multi-year) | +17.8% | — |
| Financial health | ||
| Debt to equity | 0.30 | 0.01 |
| Momentum | ||
| 1-month return | -1.6% | +3.2% |
| 1-year return | -27.3% | +26.0% |
| 3-year CAGR | +32.0% | — |
| 5-year CAGR | +25.0% | — |
| 10-year CAGR | +16.3% | — |
| Distance from 52W high | -26.6% | -4.4% |
| Technicals | ||
| RSI (14) | 57 | 81 |
| Price vs 200-day avg | -14.2% | +18.4% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Fortis Healthcare | Anthem Biosciences |
|---|---|---|
| Price above 50-day average | ✗ | ✓ |
| Price above 200-day average | ✗ | ✓ |
| 50-day average above 200-day (uptrend) | ✗ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✗ |
| Positive 1-year return | ✗ | ✓ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✗ |
| P/E below industry median | ✗ | ✗ |
| Score | 4/10 | 6/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Fortis Healthcare or Anthem Biosciences?
Fortis Healthcare has a market cap of ₹57,898 Cr and Anthem Biosciences has a market cap of ₹51,594 Cr as of 06 Nov 2026.
Which has a lower P/E, Fortis Healthcare or Anthem Biosciences?
Fortis Healthcare has the lower P/E: Fortis Healthcare trades at 55.8 and Anthem Biosciences at 271.9.
Which gave better returns in the last year, Fortis Healthcare or Anthem Biosciences?
Anthem Biosciences did better: Fortis Healthcare returned -27.3% and Anthem Biosciences returned +26.0% over one year.
Is Fortis Healthcare or Anthem Biosciences a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Fortis Healthcare scores 4/10 and Anthem Biosciences scores 6/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.